172 related articles for article (PubMed ID: 30469130)
1. Different effects of fenofibrate on cardiometabolic risk factors in young women with and without hyperprolactinemia.
Krysiak R; Szkróbka W; Okopień B
Pharmacol Rep; 2019 Feb; 71(1):61-66. PubMed ID: 30469130
[TBL] [Abstract][Full Text] [Related]
2. The effect of fenofibrate on cardiometabolic risk factors in bromocriptine-treated women with mixed dyslipidemia: A pilot study.
Krysiak R; Okrzesik J; Szkrobka W; Okopień B
Pharmacol Rep; 2016 Feb; 68(1):185-9. PubMed ID: 26721371
[TBL] [Abstract][Full Text] [Related]
3. The Effect of Atorvastatin on Cardiometabolic Risk Factors in Bromocriptine-Treated Premenopausal Women with Isolated Hypercholesterolemia.
Krysiak R; Gilowski W; Szkrobka W; Okopien B
Cardiovasc Ther; 2015 Oct; 33(5):282-7. PubMed ID: 26146893
[TBL] [Abstract][Full Text] [Related]
4. Macroprolactinaemia modulates cardiometabolic effects of fenofibrate in men with atherogenic dyslipidaemia: A pilot study.
Krysiak R; Kowalcze K; Okopień B
J Clin Pharm Ther; 2020 Feb; 45(1):115-121. PubMed ID: 31444987
[TBL] [Abstract][Full Text] [Related]
5. Different effects of cabergoline and bromocriptine on metabolic and cardiovascular risk factors in patients with elevated prolactin levels.
Krysiak R; Okopien B
Basic Clin Pharmacol Toxicol; 2015 Mar; 116(3):251-6. PubMed ID: 25123447
[TBL] [Abstract][Full Text] [Related]
6. Different Effects of Atorvastatin on Cardiometabolic Risk Factors in Young Women With and Without Hyperprolactinemia.
Krysiak R; Szkróbka W; Okopień B
J Clin Pharmacol; 2019 Jan; 59(1):83-89. PubMed ID: 30129670
[TBL] [Abstract][Full Text] [Related]
7. The Effect of Testosterone and Fenofibrate, Administered Alone or in Combination, on Cardiometabolic Risk Factors in Men with Late-Onset Hypogonadism and Atherogenic Dyslipidemia.
Krysiak R; Gilowski W; Okopien B
Cardiovasc Ther; 2015 Oct; 33(5):270-4. PubMed ID: 26031507
[TBL] [Abstract][Full Text] [Related]
8. Different effects of fenofibrate on metabolic and cardiovascular risk factors in mixed dyslipidemic women with normal thyroid function and subclinical hypothyroidism.
Krysiak R; Gilowski W; Szkrobka W; Okopien B
Cardiovasc Ther; 2014 Dec; 32(6):264-9. PubMed ID: 25290818
[TBL] [Abstract][Full Text] [Related]
9. Impact of Macroprolactinemia on Cardiometabolic Effects of Atorvastatin in Women With Hypercholesterolemia.
Krysiak R; Kowalcze K; Okopień B
Am J Cardiol; 2019 Oct; 124(8):1207-1212. PubMed ID: 31409451
[TBL] [Abstract][Full Text] [Related]
10. Cardiometabolic Risk Factors in Men with Elevated Macroprolactin Content: A Pilot Study.
Krysiak R; Szkróbka W; Okopień B
Exp Clin Endocrinol Diabetes; 2021 Jan; 129(1):7-13. PubMed ID: 31185509
[TBL] [Abstract][Full Text] [Related]
11. Vitamin D Status Determines Cardiometabolic Effects of Cabergoline in Women with Elevated Prolactin Levels: A Pilot Study.
Krysiak R; Basiak M; Machnik G; Szkróbka W; Okopień B
Nutrients; 2023 May; 15(10):. PubMed ID: 37242186
[TBL] [Abstract][Full Text] [Related]
12. Autoimmune Thyroiditis Attenuates Cardiometabolic Effects of Cabergoline in Young Women With Hyperprolactinemia.
Krysiak R; Kowalcze K; Okopień B
J Clin Pharmacol; 2023 Aug; 63(8):886-894. PubMed ID: 37042432
[TBL] [Abstract][Full Text] [Related]
13. Impaired Cardiometabolic Effects of Bromocriptine in Men With Early-Onset Androgenic Alopecia.
Krysiak R; Basiak M; Szkróbka W; Okopień B
J Clin Pharmacol; 2023 Mar; 63(3):345-351. PubMed ID: 36222207
[TBL] [Abstract][Full Text] [Related]
14. Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes.
Elam MB; Ginsberg HN; Lovato LC; Corson M; Largay J; Leiter LA; Lopez C; O'Connor PJ; Sweeney ME; Weiss D; Friedewald WT; Buse JB; Gerstein HC; Probstfield J; Grimm R; Ismail-Beigi F; Goff DC; Fleg JL; Rosenberg Y; Byington RP;
JAMA Cardiol; 2017 Apr; 2(4):370-380. PubMed ID: 28030716
[TBL] [Abstract][Full Text] [Related]
15. The effect of bromocriptine treatment on sexual functioning and depressive symptoms in women with mild hyperprolactinemia.
Krysiak R; Szkróbka W; Okopień B
Pharmacol Rep; 2018 Apr; 70(2):227-232. PubMed ID: 29475005
[TBL] [Abstract][Full Text] [Related]
16. Fenofibrate, HDL, and cardiovascular disease in Type-2 diabetes: The DAIS trial.
Tsunoda F; Asztalos IB; Horvath KV; Steiner G; Schaefer EJ; Asztalos BF
Atherosclerosis; 2016 Apr; 247():35-39. PubMed ID: 26854974
[TBL] [Abstract][Full Text] [Related]
17. Cardiometabolic risk factors in young women with macroprolactinaemia.
Krysiak R; Marek B; Okopień B
Endokrynol Pol; 2019; 70(4):336-341. PubMed ID: 30845340
[TBL] [Abstract][Full Text] [Related]
18. The impact of vitamin D status on cardiometabolic effects of fenofibrate in women with atherogenic dyslipidemia.
Krysiak R; Kowalcze K; Okopień B
Clin Exp Pharmacol Physiol; 2021 Feb; 48(2):186-194. PubMed ID: 33098674
[TBL] [Abstract][Full Text] [Related]
19. [Fibrates therapy: Rational use fenofibrate 2016. Executive summary].
Brea A; Millán J; Ascaso JF; Blasco M; Díaz A; González-Santos P; Hernández-Mijares A; Mantilla T; Pedro-Botet JC; Pintó X;
Clin Investig Arterioscler; 2016; 28(6):295-301. PubMed ID: 27609708
[TBL] [Abstract][Full Text] [Related]
20. The influence of fenofibrate on lipid profile, endothelial dysfunction, and inflammatory markers in type 2 diabetes mellitus patients with typical and mixed dyslipidemia.
Ghani RA; Bin Yaakob I; Wahab NA; Zainudin S; Mustafa N; Sukor N; Wan Mohamud WN; Kadir KA; Kamaruddin NA
J Clin Lipidol; 2013; 7(5):446-53. PubMed ID: 24079286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
